雷諾氏現象

10.6666/ClinMed.201902_83(2).0013

王愷君；蔡長祐

雷諾氏現象（Raynaud's phenomenon） ； 血管痙攣（vasospasm） ； 硬皮症（scleroderma）

臨床醫學月刊

83卷2期（2019 / 02 / 22）

67 - 74

繁體中文

雷諾氏現象（Raynaud's phenomenon）是一種不算少見的臨床症狀，可由多種不同的原因引發，有不同的預後。對臨床醫師而言，熟稔地辨別引起雷諾氏現象的原因、處理其可能引發的肢端缺血壞死等併發症，及想方設法增進患者的生活品質，均極具挑戰性。

1. Block, JA,Sequeira, W(2001).Raynaud's phenomenon.Lancet,357,2042-2048.
2. Carpentier, PH,Satger, B,Poensin, D(2006).Incidence and natural history of Raynaud phenomenon: A long-term follow-up (14 years) of a random sample from the general population.J Vasc Surg,44,1023-1028.
3. Chikura, B,Moore, TL,Manning, JB(2008).Sparing of the thumb in Raynaud's phenomenon.Rheumatology,47,219-221.
4. Coleiro, B,Marshall, SE,Denton, CP(2001).Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine.Rheumatology,40,1038-1043.
5. Cutolo, M,Pizzorni, C,Sulli, A(2007).Identification of transition from primary Raynaud's phenomenon to secondary Raynaud's phenomenon by nailfold videocapillaroscopy: comment on the article by Hirschl et al.Arthritis Rheum,56,2102-2103.
6. Dziadzio, M,Denton, CP,Smith, R(1999).Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallelgroup, controlled trial.Arthritis Rheum,42,2646-2655.
7. Ennis, H,Anderson, ME,Wilkinson, J(2014).Calcium channel blockers for primary Raynaud's phenomenon.Cochrane Database Syst
8. Flavahan, NA(2015).A vascular mechanistic approach to understanding Raynaud phenomenon.Nat Rev Rheumatol,11,146-158.
9. Freedman, RR,Mayes, MD.(1996).Familial aggregation of primary Raynaud's disease.Arthritis Rheum,39,1189-1191.
10. Khanna, D,Denton, CP,Merkel, PA(2016).Effect of macitentan on the development of new ischemic digital ulcers in patients with systemic sclerosis: DUAL-1 and DUAL-2 randomized clinical trials.JAMA,315,1975-1988.
11. Matucci-Cerinic, M,Denton, CP,Furst, DE(2011).Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial.Ann Rheum Dis,70,32-38.
12. Raynaud M. On local asphyxia and symmetrical gangrene of extremities. Barlow T, trans. London: The Sydenham Society, 1888.
13. Sulli, A,Pizzorni, C,Smith, V(2012).Timing of transition between capillaroscopic patterns in systemic sclerosis.Arthritis Rheum,64,821-825.
14. Suter, LG,Murabito, JM,Felson, DT(2005).The incidence and natural history of Raynaud's phenomenon in the community.Arthritis Rheum,52,1259-1263.
15. Thompson, AE,Pope, JE(2005).Calcium channel blockers for primary Raynaud's phenomenon: a meta-analysis.Rheumatology,44,145-150.
16. Thompson, AE,Shea, B,Welch, V(2001).Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis.Arthritis Rheum,44,1841-1847.
17. Vancheeswaran, R,Azam, A,Black, C(1994).Localization of endothelin-1 and its binding sites in scleroderma skin.J Rheumatol,21,1268-1276.
18. Wigley, FM(ed.),Herrick, AL(ed.),Flavahan, NA(ed.)(2015).Raynaud´s phenomenon: a guide to pathogenesis and treatment.New York:Springer.
19. Wigley, FM,Flavahan, NA(2016).Raynaud's Phenomenon.N Engl J Med,375,556-565.

1. (2024)。照顧一位硬皮症病人創傷之門診護理經驗。新臺北護理期刊，26(2)，155-163。